Practical Aspects of the Implementation of Screening for the Detection of Malignant Neoplasms of the Cervix during the Medical Examination

Relevance. The global strategy for cervical cancer elimination includes the active implementation of primary, secondary and tertiary prevention programs. In the Russian Federation, screening for the detection of malignant neoplasms of the cervix is carried out while women contact specialists, as well as an organized procedure during preventive medical examinations of the certain groups of adults. The study of the population structure of circulating human papillоmavirus (HPV) types, and evaluation of the effectiveness of the recommended diagnostic models will improve the direction of the fight against cervical cancer and introduce optimal preventive solutions.

Aim. Retrospective analysis of screening effectiveness for the detection of malignant neoplasms of the cervix, carried out during the medical examination in one institution of Moscow.

Materials and methods. The study examined 1068 women aged 20 to 81 years (M = 37.82, Me = 35, IQR 27–47 years) from one institution in Moscow over a 5-year follow-up period (2017–2021). The screening was based on the co-testing model: liquid-based cytology with Papanicolaou staining and classification according to the Bethesda system and quantitative Real Time HPV-test with determination of the 14 HPV DNA types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).

Results. The prevalence of the 14 HPV oncogenic types was 14.87% (95% CI: 12.86–17.13%), the most common were 16 (16.98%), 31 (14.47%), 52 (13.21%). The study determined HPV types with the highest relative risk of persistence: 33, 58, 45, and 52 (p < 0.005). The frequency of HPV detection depended on the age of the examined women and was the highest in the age group of 20–29 years (25.58%). The baseline prevalence was 11.82% (95% CI: 9.98–13.94%). 6 HSIL cases associated with HPV types 16 and 31 were identified. 4/6 were in women under 30 years. The probability of intraepithelial lesions of the cervix increased with an increase of HPV DNA concentration: 23.65% and 66.67% with a viral load of 4.0–6.0 lg copies per 105 human cells and > 6.0 lg copies per 105 human cells, respectively.

Conclusions. The study confirmed the great value of HPV- test in screening for the detection of malignant neoplasms of the cervix during the medical examination of the certain groups of adult population, taking into account the advantages of typing and quantitative determination of HPV DNA, as well as the need to consider lowering of the recommended age for the start of HPV-testing.

1. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. Available at: https:.www.who.int/publications/i/item/9789240030824. Accessed: 23 May 2023.

2. Spayne J, Hesketh T. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. BMJ Open. 2021;11(9):e052016. Published 2021 Sep 2. doi:10.1136/bmjopen-2021-052016

3. Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev. 2020;8(1):28–37. doi:10.1016/j.sxmr.2019.09.005

4. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol. 2010;21(3):448– 458. doi:10.1093/annonc/mdp471

5. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–346. doi:10.3322/caac.21628

6. Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–e27. doi:10.1016/S2468-2667(18)30183-X

7. Natsionalnij proekt «Zdravoohranenie», Federalnij proekt “Borba s onkologicheskimi zabolevanijami”. Ministerstvo Zdravoohranenija Rossijskoy Federatsii Available at: https:.minzdrav.gov.ru/poleznye-resursy/natsproektzdravoohranenie/onko. Accessed: 23 May 2023. (In Russ).

8. Tservikalnaja intraepitelialnaja neoplasia, erosia i ektropion shejki matki. Klinicheskie rekomendatsii. Ministerstvo Zdravoohranenija Rossijskoy Federatsii 2020. Available at: https:.cr.minzdrav.gov.ru/recomend/597_1. Accessed: 23 May 2023 (In Russ).

9. Vzatije, transportirovka, hranenije klinicheskogo materiala dlia PCR-diagnostiki. Metodicheskoje posobije. Tsentralnij nauchno-issledovatelskij institut epidemiologii 2012. Available at: https:.interlabservice.ru/consulting/adv/files/transporting_store.pdf/. Accessed: 23 May 2023. (In Russ).

10. Domonova E.A., Popova A.A., Kuleshova O.B., et al. Raspostranennost virusa papillomi cheloveka razlichnogo kantserogennogo riska sredi naselenija Moskovskogo regiona. Svidetelstvo o registratsii bazi dannih №2022621655. 07.07.2022. (In Russ).

11. Rogovskaya S.I., Mikheeva I.V., Shipulina O.Yu. Prevalence of human papillomavirus in Russia (Review). Epidemiology and Vaccinal Prevention. 2012;1(62):25–33 (In Russ).

12. Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–1799. doi:10.1086/657321

13. Zykova T.A., Nerodo G.A., Bogomolova O.A., et al. Prevalence, viral load and types diversity of high-risk HPV in patients with inflammatory and tumor diseases. Medical Herald of the South of Russia. 2018;9(1):42–50. doi:10.21886/2219-8075-2018-9-1-42-50 (In Russ).

14. Chimitdorzhiyeva T.N., Shmatkova A.M., Akhmatkhanov Kh.U., et al. Prevalence HPV High Carcinogenic risk among the women population of the Republic of Buryatia. Effectivnaya farmakoterapiya. 2021;17(15):10–14. doi: 10.33978/2307-3586-2021-17-15-10-14 (In Russ).

15. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1–K16. doi:10.1016/j.vaccine.2008.05.064

16. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159. doi:10.1016/S0140-6736(17)31821-4

17. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials [published correction appears in Lancet. 2015 Oct 10;386(10002):1446]. Lancet. 2014;383(9916):524–532. doi:10.1016/S0140-6736(13)62218-7

18. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095– 1101. doi:10.1002/ijc.21955

19. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–819. doi:10.7326/0003-4819-132-10-200005160-00009

20. Kaprin AD, Aleksandrova LM, Starinskij VV, et al. Medical prophylactic examination of certain adult population groups from Russia as a tool for the early detection of malignant neoplasms (the 2015–2016 results). Profilakticheskaya Meditsina. 2018;21(4):13–19 (In Russ). doi:10.17116/profmed201821413

21. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97(12):888–895. doi:10.1093/jnci/dji162.

22. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer. 2012;106(9):1571–1578. doi:10.1038/bjc.2012.94

23. Kim JJ, Campos NG, Sy S, et al. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. Ann Intern Med. 2015;163(8):589–597. doi:10.7326/M15-0420

24. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13. doi:10.1016/j.bpob-gyn.2017.08.015

25. Dong B., Sun P., Ruan G., et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high grade squamosus ontraepithelial lesion: a nested case-control study // Cancer Manag.Res.2018.Vol10.P4839-4851

26. Dong B, Sun P, Ruan G, et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested casecontrol study. Cancer Manag Res. 2018;10:4839–4851. Published 2018 Oct 23. doi:10.2147/CMAR.S179724

27. Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1816–1824. doi:10.1158/1055-9965.EPI-19-0239

28. KaprinAD, Starinskij VV, Shahzadova AO, editors. Zlokachestvennije novoobrazovanija v Rossii v 2020 godu (zabolevaemost i smertnost). Moscow: MNIOI im P.A. Gertcena – filial FGBU «NMIC radiologii» Minzdrava Rossii; 2021. Available at: https:.oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf. (In Russ).